OPKO’s GeneDx Subsidiary and North Shore-LIJ Health System Form Strategic Alliance for Genetic Testing

MIAMI, Dec. 14, 2015 /PRNewswire/ — The North Shore-LIJ Health System and OPKO Health, Inc. (NYSE: OPK) have formed a novel strategic alliance to provide genomic testing, molecular diagnostic testing and ancillary support services such as genetic counseling.  The scope of testing will cover all genetic disorders, including prenatal screening, pediatric and postnatal diagnosis, assessing risk for inherited cancer, and testing […]

OPKO’s GeneDx Study Demonstrates Whole Exome Sequencing Usefulness In Diagnosing Rare Disorders

Study reveals new disease causing genes MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) announced today through its subsidiary GeneDx, results from a retrospective review of molecular diagnostic testing by Whole Exome Sequencing (WES). The peer-reviewed study, “Clinical Application of Whole Exome Sequencing across Clinical Indications,” was published in the December 2015 issue of Genetics in Medicine. It is the largest data […]

OPKO 4Kscore Test Receives Category I CPT Code Approval

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) announced today that the American Medical Association (AMA) Current Procedural Terminology (CPT®) Editorial Panel has granted a Category I CPT code for its 4Kscore® Test, the only blood test that accurately identifies an individual patient’s risk for aggressive prostate cancer. This important event upgrades the 4Kscore Test from a Category III Administrative code to a […]

OPKO Health Refinances Bio-Reference Laboratories Credit Facility

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) today announced today that it has successfully closed on a new five-year $175.0 million secured revolving credit facility with JPMorgan Chase. The new facility replaced Bio-Reference Laboratories’ previous $120.0 million secured revolving credit facility. “We are excited to enter into a partnership with one of the world’s premier banking institutions, JPMorgan Chase,” commented Phillip Frost, MD, Chairman & […]

OPKO Health’s GeneDx Business Presenting at National Society of Genetic Counselors Annual Meeting

Focus is on Genetic Diagnosis of Rare Disease PITTSBURGH–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) announced today that GeneDx, a business unit of OPKO will be presenting at the National Society of Genetic Counselors (NSGC) 34th Annual Education Conference in Pittsburgh, PA. GeneDx staff and genetic counselors will participate at the conference as individual speakers, poster presenters and exhibitors. GeneDx is also sponsoring a networking […]

OPKO Completes Acquisition of Bio-Reference Laboratories

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE: OPK) and BioReference Laboratories, Inc. (NASDAQ: BRLI) today announced the completion of the acquisition of BioReference by OPKO. Shareholders of BioReference will receive 2.75 shares of OPKO common stock for each share of BioReference common stock.  “The acquisition of Bio-Reference is important for OPKO,” commented Dr. Phillip Frost, OPKO’s Chairman and Chief […]

OPKO Lab Signs Contracts with Leading Preferred Provider Networks for Laboratory Testing Services Including the 4Kscore® Test

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) today announced that it has entered into agreements with Stratose, Three Rivers Provider Network and Fortified Provider Network for testing services from OPKO Lab, including the 4Kscore®Test, the only blood test that accurately identifies an individual patient’s risk for high-grade, aggressive cancer. The cumulative contracts, with some of the largest healthcare PPO network […]

OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned Acquisition

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (OPK) and Bio-Reference Laboratories, Inc. (BRLI), today announced that early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) has been granted, effective July 1, 2015, for OPKO’s planned acquisition of Bio-Reference. This Smart News Release features multimedia. View the full release here: www.businesswire.com/news/home/20150702005579/en/ Expiration of the waiting period […]

OPKO 4Kscore® Recommended in National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) today announced the decision of the National Comprehensive Cancer Network (NCCN) to include 4Kscore® as a recommended test in the 2015 NCCN Guidelines for Prostate Cancer Early Detection. The panel concluded that the 4Kscore, as a blood test with greater specificity over the PSA test, is indicated for use prior to a first […]

OPKO and Bio-Reference Laboratories To Hold Joint Conference Call to Discuss Merger

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) and Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) will host a joint conference call and webcast at 8:30 a.m. ET on Thursday, June 11, 2015, to discuss the previously announced entry into a merger agreement for OPKO to acquire Bio-Reference Laboratories and to discuss Bio-Reference Laboratories’ second quarter financial results. This joint call will be in lieu of the separate earnings […]